About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Teijin Ltd. et al. v. Lupin Ltd. et al.
1:14-cv-00184; filed February 12, 2014 in the District Court of Delaware

• Plaintiffs:  Teijin Ltd.; Teijin Pharma Ltd.; Takeda Pharmaceuticals USA Inc.
• Defendants:  Lupin Ltd.; Lupin Pharmaceuticals Inc.

Teijin Ltd. et al. v. Hetero USA Inc. et al.
1:14-cv-00166; filed February 7, 2014 in the District Court of Delaware

• Plaintiffs:  Teijin Ltd.; Teijin Pharma Ltd.; Takeda Pharmaceuticals USA Inc.
• Defendants:  Hetero USA Inc.; Hetero Labs Ltd.

The complaints in these cases are substantially identical.  Infringement of U.S. Patent No. 6,225,474 ("Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and Method of Producing the Same," issued May 1, 2001) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Takeda's Uloric® (febuxostat, used for the chronic management of hyperuricemia in patients with gout).  View the Hetero complaint here.

Fresenius Kabi USA LLC v. Dr. Reddy's Laboratories Ltd. et al.
1:14-cv-00160; filed February 6, 2014 in the District Court of Delaware

• Plaintiff:  Fresenius Kabi USA LLC
• Defendants:  Dr. Reddy's Laboratories Ltd.; Dr. Reddy's Laboratories Inc.

Fresenius Kabi USA LLC v. Watson Laboratories Inc. et al.
1:14-cv-00161; filed February 6, 2014 in the District Court of Delaware

• Plaintiff:  Fresenius Kabi USA LLC
• Defendants:  Watson Laboratories Inc.; Actavis Inc.

The complaints in these cases are substantially identical.  Infringement of U.S. Patent No. 8,476,010 ("Propofol Formulations with Non-Reactive Container Closures," issued July 2, 2013) following a Paragraph IV certification as part of defendats' filing of an ANDA to manufacture a generic version of Fresenius' Diprivan® (propofol injectable emulsion, used for the induction and maintenance of general anesthesia and sedation in certain patient populations).  View the Dr. Reddy's complaint here.

Forest Laboratories Inc. et al. v. Glenmark Generics Inc. USA et al.
1:14-cv-00159; filed February 6, 2014 in the District Court of Delaware

• Plaintiffs:  Forest Laboratories Inc.; Forest Laboratories Holdings Ltd.; Royalty Pharma Collection Trust
• Defendants:  Glenmark Generics Inc. USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.

Infringement of U.S. Patent Nos. 6,602,911 ("Methods of Treating Fibromyalgia," issued August 5, 2003), 7,888,342 ("Methods of Treating Fibromyalgia Syndrome, Chronic Fatigue Syndrome and Pain," issued February 15, 2011), and 7,994,220 ("Milnacipran for the Long-Term Treatment of Fibromyalgia Syndrome," issued August 9, 2011), all licensed to Forest, following a Paragraph IV certification as part of Glenmark's filing of an ANDA to manufacture a generic version of Forest's Savella® (milnacipran hydrochloride, used in the management of fibromyalgia).  View the complaint here.

Novartis Pharmaceuticals Corp. et al. v. Dr. Reddy's Laboratories, Ltd. et al.
2:14-cv-00785; filed February 6, 2014 in the District Court of New Jersey

• Plaintiffs:  Novartis Pharmaceuticals Corp.; Novartis AG
• Defendants:  Dr. Reddy's Laboratories, Ltd.; Dr. Reddy's Laboratories, Inc.

Infringement of U.S. Patent No. 6,894,051 ("Crystal Modification of a N-phenyl-2-pyrimidineamine Derivative, Processes for Its Manufacture and Its Use," issued May 17, 2005) following a Paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of Novartis' Gleevec® (imatinib mesylate, used for various indications, including treatment of myeloid leukemia).  View the complaint here.